Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive results in its Phase 2 clinical trial, in which SGX942, a first-in-class Innate Defense Regulator (IDR), at a dose of 1.5 mg/kg, successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer.

16 Dec 2015

Hematopoietic stem cell transplantation does not provide improvement for patients with Crohn disease

Among adults with difficult to treat Crohn disease not amenable to surgery, hematopoietic stem cell transplantation, compared with conventional therapy, did not result in significant improvement in sustained disease remission at l year and was associated with significant toxicity, according to a study in the December 15 issue of JAMA.

16 Dec 2015

Human-gut-on-a-chip model offers hope for patients suffering from IBD

It's estimated that as many as 1,000,000 Americans suffer from inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, which cause mild to severe symptoms that at best can be managed and at worst can lead to life-threatening complications.

16 Dec 2015

Lupuzor may become first non-immunosuppressant therapy for lupus

Lupuzor may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable.

15 Dec 2015

IBD Plexus brings patients, researchers and doctors together to create IBD research initiative

For the first time, more than 40,000 IBD patients, researchers, and healthcare providers will be brought together by IBD Plexus to create the world's largest registry of IBD patients of all ages which will transform how IBD research is being conducted.

12 Dec 2015

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor.

8 Dec 2015

Genetic information of patients with IBD could provide road map for more effective treatments

Genetic variation in patients with inflammatory bowel disease (IBD) appears to play a major role in determining how sick they will become and could provide a road map for more effective treatments.

1 Dec 2015

High-fat diet appears to prompt immune cells to start consuming connections between neurons

When a high-fat diet causes us to become obese, it also appears to prompt normally bustling immune cells in our brain to become sedentary and start consuming the connections between our neurons, scientists say.

24 Nov 2015

Research findings may lead to potential therapeutic target for treating inflammatory bowel diseases

UT Southwestern Medical Center researchers have shown that a pathogen-sensing molecule plays a vital role in keeping gastrointestinal (GI) systems healthy.

20 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Some gut microbes may hold the key to regulating good health, say Oregon scientists

University of Oregon scientists have found that strength in numbers doesn't hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.

12 Nov 2015

Saint Louis University ophthalmologist offers tips to manage night vision issues

Owls and cats are at an advantage as the days get darker, but humans may notice their vision takes a hit during their evening commute home as daylight hours shrink.

31 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

Different Crohn's disease treatments affect children's gut microbes in distinct ways

Different treatments for Crohn's disease in children affects their gut mi-crobes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

15 Oct 2015

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists have calculated more precise measurements of heritability--the influence of underlying genes--in nine autoimmune diseases that begin in childhood. The research may strengthen researchers' abilities to better predict a child's risk for associated autoimmune diseases.

9 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Premature infants have heightened risks of deadly diseases because their organs and immune systems are not fully developed. Necrotizing enterocolitis (NEC), a major gastrointestinal disease that causes the intestines to die, is a leading cause of death among these infants and is the most the common disease for babies born before 32 weeks.

1 Oct 2015

Common IBD therapeutic target may protect against intestinal inflammation

Investigators at Children's Hospital Los Angeles have found that a common therapeutic target for the treatment of inflammatory bowel disease (IBD) may actually protect against intestinal inflammation by inhibiting pathogenic T-cells. This discovery, reported in the October 2015 issue of Gastroenterology, could lead to new treatment options for the 65 percent of individuals with IBD who do not respond or become resistant to anti-TNF medications.

26 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Hematopoietic stem cell transplantation does not provide improvement for patients with Crohn disease

Human-gut-on-a-chip model offers hope for patients suffering from IBD

Lupuzor may become first non-immunosuppressant therapy for lupus

IBD Plexus brings patients, researchers and doctors together to create IBD research initiative

New way to antagonize human nuclear receptor

Genetic information of patients with IBD could provide road map for more effective treatments

High-fat diet appears to prompt immune cells to start consuming connections between neurons

Research findings may lead to potential therapeutic target for treating inflammatory bowel diseases

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Some gut microbes may hold the key to regulating good health, say Oregon scientists

Saint Louis University ophthalmologist offers tips to manage night vision issues

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Different Crohn's disease treatments affect children's gut microbes in distinct ways

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Common IBD therapeutic target may protect against intestinal inflammation

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in